← Eichor
Study identifier: NCT04824053 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Effects of UNICLA-A2 Dairy Products on Patients at High-risk of Colorectal Cancer Development

Condition: Colorectal Polyp  ·  Sponsor: Instituto de Investigación Sanitaria Aragón

PhaseNA
Planned participants34
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

Dietary intervention with UNICLA-A2 milk products containing beta casein A2 protein, and higher levels of omega-3 fatty acids and selenium may contribute to maintain the intestinal integrity, reduce inflammatory processes, normalize the immune system, protect against oxidative damage and equilibrate the gut microbiota in high-risk colorectal cancer patients who have undergone polypectomy

This description comes directly from the study's public registry record.

Talk to the study team

Angel Lanas Arbeloa, MD, PhD  ·  0034 976 76 57 86  ·  alanas@unizar.es

Pilar Irun, PhD  ·  mpirun.uit@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Angel Lanas ArbeloaZaragoza, Zaragoza, SpainRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04824053